The prognostic marker NRIP1 is associated with tumor progression and immune infiltration in acute myeloid leukemia.

Acute myeloid leukemia (AML) is a clinically aggressive hematologic malignancy characterized by high relapse rates and treatment resistance, highlighting the need for novel biomarkers to improve clinical outcomes. In this study, we explore the roles…

Preview only. Read the full abstract at the source